BioPharma Drug Discovery

Toshiba's Heavy Ion Therapy System treats patients at Yonsei University Health System.

Toshiba Energy Systems & Solutions Corporation (hereinafter "Toshiba ESS") is pleased to announce today the commencement of treatment using a heavy ion...

 April 30, 2023 | News

Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit

The newly created business leverages the acclaimed team and production facility recently acquired by Bridgewest Group from Pfizer (Perth) Pty Ltd, a subsid...

 April 26, 2023 | News

Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies

Cerner Enviza, an Oracle company, along with John Snow Labs, are now helping support the U.S. Food and Drug Administration’s drug safety Se...

 April 25, 2023 | News

How digitally mature is your QMS?

        How digitally mature is your QMS? &nbs...

 April 25, 2023 | News

LTS acquires Sorrel for large molecule drug delivery

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such a...

 April 21, 2023 | News

CARsgen's CT041 receives IND clearance from NMPA for pancreatic cancer therapy.

Dr Raffaele Baffa, Chief Medical Officer of CARsgen, commented that "We are glad to receive the IND clearance from NMPA for the adjuvant treatment of ...

 April 20, 2023 | News

Samyang Holdings partners with LG Chem for innovative cancer therapeutics.

Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of nove...

 April 20, 2023 | News

Everest Medicines partners with Shanghai Pharma subsidiary to commercialize XERAVA in China

According to the MoU, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline) in China. SPH Kyuan'...

 April 19, 2023 | News

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

 April 13, 2023 | News

Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...

 April 13, 2023 | News

Discovery Life Sciences Acquiert Reachbio Research Labs

 Discovery Life Sciences™ (Discovery), Biospecimen and Biomarker Specialists, has acquired Seattle-based ReachBio Research L...

 April 12, 2023 | News

Asieris subsidiary obtains "Drug Distribution License" for commercialization strategy.

Hainan Asieris' acquisition of the Drug Distribution Licence is a critical step towards improvement in the quality of drug circulation services, standardiz...

 April 11, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

 April 10, 2023 | News

Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA Nephropathy Treatment

 Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commerc...

 April 06, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close